Gold nanoparticles as antiangiogenic and antimetastatic agents

被引:6
|
作者
Zamborlin, Agata [1 ,2 ]
Voliani, Valerio [1 ,3 ]
机构
[1] Ist Italiano Tecnol, Ctr Nanotechnol Innovat NEST, Piazza San Silvestro 12, I-56127 Pisa, Italy
[2] NEST Scuola Normale Super, Piazza San Silvestro 12, I-56127 Pisa, Italy
[3] Univ Genoa, Dept Pharm, Viale Cembrano 4, I-16148 Genoa, Italy
关键词
oncology; angiogenesis; metastasis; nanomedicine; nanoparticles; theranostics; ENDOTHELIAL GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; HEPARIN INDUCES APOPTOSIS; CANCER-CELL MIGRATION; TUMOR ANGIOGENESIS; MACROMOLECULAR THERAPEUTICS; MOLECULAR-MECHANISMS; DOUBLE-BLIND; PHASE-II; METASTASIS;
D O I
10.1016/j.drudis.2022.103438
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiogenesis and metastasis are two interdependent cancer hallmarks, the latter of which is the key cause of treatment failure. Thus, establishing effective antiangiogenesis/antimetas tasis agents is the final frontier in cancer research. Gold nanoparticles (GNPs) may provide disruptive advancements in this regard due to their intrinsic physical and physiological features. Here, we comprehensively discuss recent potential therapeutical strategies to treat angiogenesis and metastasis and present a critical review on the state-of-the-art in vitro and in vivo evaluations of the antiangiogenic/antimetastatic activity of GNPs. Finally, we provide perspectives on the contribution of GNPs to the advancement of cancer management.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Chemistry and biology in search of antimetastatic agents
    Perez, Lucy
    Danishefsky, Samuel J.
    ACS CHEMICAL BIOLOGY, 2007, 2 (03) : 159 - 162
  • [32] Novel antiangiogenic agents in dermatology
    Berrios, Ricardo L.
    Arbiser, Jack L.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2011, 508 (02) : 222 - 226
  • [33] Antiangiogenic Agents in Multiple Myeloma
    Kumar, Shaji
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S44 - S45
  • [34] Beyond Bevacizumab: Antiangiogenic Agents
    Rogosin, Shane
    Sandler, Alan B.
    CLINICAL LUNG CANCER, 2012, 13 (05) : 326 - 333
  • [35] Antiangiogenic agents and gastrointestinal cancers
    Lievre, A.
    Landi, B.
    Mitry, E.
    Taieb, J.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2008, 32 (05): : 504 - 520
  • [36] Antiangiogenic agents for the treatment of glioblastoma
    Gerstner, Elizabeth R.
    Duda, Dan G.
    di Tomaso, Emmanuelle
    Sorensen, Greg
    Jain, Rakesh K.
    Batchelor, Tracy T.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (12) : 1895 - 1908
  • [37] Molecular imaging of antiangiogenic agents
    Rehman, S
    Jayson, GC
    ONCOLOGIST, 2005, 10 (02): : 92 - 103
  • [38] Antiangiogenic agents and targets: A perspective
    Teicher, Beverly A.
    BIOCHEMICAL PHARMACOLOGY, 2011, 81 (01) : 6 - 12
  • [39] Translation of indibulin (ZIO-301) preclinical antiangiogenic and antimetastatic activity to the clinic
    Schwartz, Brian
    Bacher, Gerald
    Komarnitsky, Philip
    Rosen, Lee
    Chawla, Sant
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3522S - 3522S
  • [40] Effect of reducing agents on the synthesis of anisotropic gold nanoparticles
    Yoo, Sunghoon
    Nam, Dong Hwan
    Singh, Thangjam Ibomcha
    Leem, Gyu
    Lee, Seunghyun
    NANO CONVERGENCE, 2022, 9 (01)